Literature DB >> 17656103

Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.

Flavia Mulè1, Antonella Amato, Sara Baldassano, Rosa Serio.   

Abstract

While most of the studies concerning the role of cannabinoids on gastric motility have focused the attention on the gastric emptying in in vivo animal models, there is little information about the cannabinoid peripheral influence in the stomach. In addition, the functional features of CB2 receptors in the gastrointestinal tract have been poorly characterized. The purpose of the present study was to investigate the effects of cannabinoid drugs on the excitatory cholinergic and inhibitory non-adrenergic non-cholinergic (NANC) neurotransmission in mouse isolated gastric preparations. Intraluminal pressure from isolated whole stomach was recorded and mechanical responses induced by electrical field stimulation (EFS) were analyzed in different experimental conditions. EFS (0.5ms duration, supramaximal voltage, in trains of 5s, 2-16Hz) caused a cholinergic contraction, which was abolished by atropine or tetrodotoxin (TTX). The cannabinoid receptor agonist, WIN 55,212-2, the endogenous ligand, anandamide, the selective CB1 receptor agonist ACEA, and the selective CB2 receptor agonists, JWH015 and JWH133, produced a concentration-dependent reduction of the EFS-evoked cholinergic contractions. SR141716A, CB1 receptor antagonist, significantly attenuated the inhibitory effects induced by WIN 55,212-2, anandamide or ACEA, without affecting those caused by JWH133. AM630, CB2 receptor antagonist, reduced the inhibitory effects induced by WIN 55,212-2, anandamide, JWH015 or JWH133, without affecting those caused by ACEA. The joint application of SR141716A and AM630 was able of fully preventing the WIN 55,212-2 and anandamide actions. The cannabinoid antagonists failed per se to affect the neurally evoked responses. Cannabinoids did not modify the contractions produced by exogenous carbachol. In the presence of atropine and guanethidine (NANC conditions) EFS-induced TTX-sensitive relaxation consisting in an early and rapid component followed by a second slow phase, which were unaffected by cannabinoid drugs. In conclusion, the present results suggest that cannabinoids play a prejunctional modulatory role on the cholinergic excitatory transmission without affecting the NANC inhibitory transmission. In addition, this study provides experimental evidence that also the activation of CB2 receptors is able to reduce cholinergic neurotransmission in the mouse stomach.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17656103     DOI: 10.1016/j.phrs.2007.06.002

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  17 in total

1.  Modulation of gastric motility by brain-gut peptides using a novel non-invasive miniaturized pressure transducer method in anesthetized rodents.

Authors:  Guillaume Gourcerol; David W Adelson; Mulugeta Million; Lixin Wang; Yvette Taché
Journal:  Peptides       Date:  2011-01-22       Impact factor: 3.750

2.  Guanosine negatively modulates the gastric motor function in mouse.

Authors:  Maria Grazia Zizzo; Flavia Mulè; Antonella Amato; Francesca Maiorana; Giuseppa Mudò; Natale Belluardo; Rosa Serio
Journal:  Purinergic Signal       Date:  2013-07-10       Impact factor: 3.765

3.  Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.

Authors:  M A Storr; M Bashashati; C Hirota; V K Vemuri; C M Keenan; M Duncan; B Lutz; K Mackie; A Makriyannis; W K Macnaughton; K A Sharkey
Journal:  Neurogastroenterol Motil       Date:  2010-02-24       Impact factor: 3.598

4.  Systemic Injections of Cannabidiol Enhance Acetylcholine Levels from Basal Forebrain in Rats.

Authors:  Eric Murillo-Rodríguez; Gloria Arankowsky-Sandoval; Nuno Barbosa Rocha; Rodrigo Peniche-Amante; André Barciela Veras; Sérgio Machado; Henning Budde
Journal:  Neurochem Res       Date:  2018-06-06       Impact factor: 3.996

5.  In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.

Authors:  R Abalo; C Chen; G Vera; J Fichna; G A Thakur; A E López-Pérez; A Makriyannis; M I Martín-Fontelles; M Storr
Journal:  Neurogastroenterol Motil       Date:  2015-09-20       Impact factor: 3.598

6.  Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors.

Authors:  R Capasso; F Borrelli; M G Cascio; G Aviello; K Huben; J K Zjawiony; P Marini; B Romano; V Di Marzo; F Capasso; A A Izzo
Journal:  Br J Pharmacol       Date:  2008-07-14       Impact factor: 8.739

7.  Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats.

Authors:  Marnie Duncan; Abdeslam Mouihate; Ken Mackie; Catherine M Keenan; Nancy E Buckley; Joseph S Davison; Kamala D Patel; Quentin J Pittman; Keith A Sharkey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-15       Impact factor: 4.052

8.  A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain.

Authors:  Iryna A Khasabova; Sergey G Khasabov; Catherine Harding-Rose; Lia G Coicou; Bryan A Seybold; Amy E Lindberg; Christopher D Steevens; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2008-10-29       Impact factor: 6.167

9.  The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet.

Authors:  V Di Marzo; R Capasso; I Matias; G Aviello; S Petrosino; F Borrelli; B Romano; P Orlando; F Capasso; A A Izzo
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

10.  Modulation of motor and sensory pathways of the peristaltic reflex by cannabinoids.

Authors:  John R Grider; Sunila Mahavadi; Yan Li; Li-Ya Qiao; John F Kuemmerle; Karnam S Murthy; Billy R Martin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-09       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.